Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:gonadotropin-releasing_hormone_agonist |
| gptkbp:approvedBy |
gptkb:FDA
1987 |
| gptkbp:ATCCode |
gptkb:L02AE03
|
| gptkbp:brand |
gptkb:Zoladex
|
| gptkbp:CASNumber |
gptkb:65807-02-5
|
| gptkbp:category |
fertility medicine
hormonal antineoplastic agent |
| gptkbp:chemicalFormula |
C59H84N18O14
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
2-4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
goserelin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
suppresses production of sex hormones
|
| gptkbp:molecularWeight |
1269.4 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
mood changes
bone pain injection site reactions hot flashes sexual dysfunction |
| gptkbp:usedFor |
gptkb:cancer
prostate cancer assisted reproduction endometriosis uterine fibroids |
| gptkbp:bfsParent |
gptkb:Zoladex
|
| gptkbp:bfsLayer |
7
|